{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=45", "query": { "intervention": "PLACEBO", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 33116, "total_pages": 3312, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T13:39:03.381Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07318610", "title": "Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral Artery Disease (PAD)" ], "interventions": [ { "name": "REGN7508", "type": "DRUG" }, { "name": "REGN9933", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7050, "start_date": "2026-07-10", "completion_date": "2029-11-16", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 27, "location_summary": "Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 23 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Alexander City", "state": "Alabama" }, { "city": "Avondale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318610" }, { "nct_id": "NCT00782210", "title": "12 / 48 Week Pivotal PFT vs PBO in COPD I", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Olodaterol (BI1744)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 625, "start_date": "2008-11", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 21, "location_summary": "Jasper, Alabama • Berkeley, California • Los Angeles, California + 17 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Stamford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00782210" }, { "nct_id": "NCT02061813", "title": "Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head Lice" ], "interventions": [ { "name": "Abametapir Lotion 0.74% w/w", "type": "DRUG" }, { "name": "Sodium Lauryl Sulfate", "type": "DRUG" }, { "name": "Saline 0.9%", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dr. Reddy's Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2014-01", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2021-07-26", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 1, "location_summary": "Paramus, New Jersey", "locations": [ { "city": "Paramus", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061813" }, { "nct_id": "NCT04644120", "title": "Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CoronaVirus Disease-2019 (COVID-19)" ], "interventions": [ { "name": "ABBV-47D11", "type": "DRUG" }, { "name": "Placebo for ABBV-47D11", "type": "DRUG" }, { "name": "ABBV-2B04", "type": "DRUG" }, { "name": "Placebo for ABBV-2B04", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-12-10", "completion_date": "2021-08-24", "has_results": false, "last_update_posted_date": "2021-09-02", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 11, "location_summary": "Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Cutler Bay", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644120" }, { "nct_id": "NCT04762758", "title": "Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Charcot-Marie-Tooth Disease" ], "interventions": [ { "name": "(RS)-baclofen, naltrexone hydrochloride and D-sorbitol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharnext S.C.A.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 350, "start_date": "2021-03-30", "completion_date": "2024-04-19", "has_results": false, "last_update_posted_date": "2024-04-03", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 20, "location_summary": "Los Angeles, California • Sacramento, California • New Britain, Connecticut + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04762758" }, { "nct_id": "NCT00347555", "title": "Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Plasmodium Falciparum Malaria" ], "interventions": [ { "name": "Aluminum Phosphate", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "EBA-175 RII-NG Malaria Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 80, "start_date": "2006-05", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2013-04-12", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00347555" }, { "nct_id": "NCT06229678", "title": "Ketones, SGLT2, HFrEF", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Type2diabetes", "Heart Failure With Reduced Ejection Fraction" ], "interventions": [ { "name": "Empagliflozin 25 MG Oral Tablet", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Acipimox 250 Mg Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 71, "start_date": "2024-01-25", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06229678" }, { "nct_id": "NCT06173778", "title": "Semaglutide for Post-Smoking Cessation Weight Management", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity", "Overweight", "Cigarette Smoking" ], "interventions": [ { "name": "semaglutide 2.4mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Nicotine Replacement Therapy (NRT, nicotine patch)", "type": "DRUG" }, { "name": "Brief Smoking Cessation Counseling", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 197, "start_date": "2024-04-23", "completion_date": "2028-06-25", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 2, "location_summary": "Austin, Texas • Houston, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06173778" }, { "nct_id": "NCT00013585", "title": "Safety and Effectiveness of the Selegiline \"Patch\" for Decreased Mental Function in HIV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognition Disorders", "HIV Infections" ], "interventions": [ { "name": "Selegiline hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": null, "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 15, "location_summary": "Los Angeles, California • San Diego, California • Honolulu, Hawaii + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00013585" }, { "nct_id": "NCT02030925", "title": "Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Reflux" ], "interventions": [ { "name": "IW-3718", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ironwood Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 93, "start_date": "2014-02", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2016-08-01", "last_synced_at": "2026-10-29T13:39:03.381Z", "location_count": 10, "location_summary": "North Little Rock, Arkansas • Anaheim, California • Monroe, Louisiana + 7 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Monroe", "state": "Louisiana" }, { "city": "Chesterfield", "state": "Michigan" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02030925" } ] }